PoxelFRA:7PO -4.71%37 Pretax Margin % is -119.88% as of Jun. 2025. GuruFocus rates FRA:7PO with a GF Score™ of 37/100 and a GF Value™ of €1.09 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Poxel ranks worse than 58.16% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Poxel's Pre-Tax Income for the
six
months ended in Jun. 2025 was €-2.62 Mil. Poxel's Revenue for the
six
months ended in Jun. 2025 was €2.18 Mil. Therefore, Poxel's pretax margin for the quarter that ended in Jun. 2025 was -119.88%.
The historical rank and industry rank for Poxel's Pretax Margin % or its related term are showing as below:
FRA:7PO'
s Pretax Margin % Range Over the Past 10 Years
Min: -34975.71 Med: -444.33 Max: 2.21
Current: -178.43
FRA:7PO's Pretax Margin % is ranked worse than 58.16% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs FRA:7PO: -178.43
Poxel (FRA:7PO) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Poxel Pretax Margin % Related Terms
Poxel Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Poxel's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7PO vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Poxel's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poxel Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poxel's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Poxel's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poxel (FRA:7PO) has a Pretax Margin % of -119.88% as of Jun. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Poxel and its competitors. According to the industry distribution chart, Poxel ranks #549 out of 944 companies in the Biotechnology industry, placing it in the top 58.2%.
Is Poxel's Pretax Margin % too high?
Poxel's current Pretax Margin % is -119.88%. Based on the distribution chart, Poxel ranks #549 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Poxel has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poxel ranks #549 out of 944 companies for Pretax Margin %. This places Poxel in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Poxel and its competitors. Poxel's current Pretax Margin % is -119.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (FRA:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.09, compared to a current price of €0.19 — trading 82.2% below its estimated fair value. The current Pretax Margin % is -119.88%. Poxel's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Poxel (FRA:7PO), the current Pretax Margin % is -119.88% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poxel (FRA:7PO) Overvalued in 2026?
Based on GuruFocus' analysis, Poxel stock appears to be undervalued.
The current stock price of €0.19 is trading 82.2% below its estimated GF Value™ of €1.09.
GuruFocus considers Poxel to be Possible Value Trap.
Key valuation signals for FRA:7PO:
Pretax Margin %: -119.88%
GF Value™: €1.09 vs. price of €0.19 (82.2% below fair value)
No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score
Get the complete analysis for FRA:7PO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7PO has been successfully added to your 
